1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Healthconn Corp.

Healthconn Corp.

6665.TWO
Healthconn Corp.TW flagTaipei Exchange
21.00
TWD
- -
- -
952.35MMarket Cap
Healthconn Corp.
6665.TWO
(Taipei Exchange)

Recent

price

21.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
4.88
7.85
10.23
24.47
38.22
43.36
33.41
30.24
34.11
27.69
27.62
- -
Revenue per Share
0.3
3.03
3.78
5.07
5.99
6.32
2.62
0.83
0.56
0.05
0.42
- -
Basic EPS, GAAP
-1.65
5.46
2.55
5.75
5.04
6.87
6.54
1.11
2.14
1.06
-0.07
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
2.83
3.33
4.53
2.28
0.71
0.46
0.05
- -
Dividend per Share
11.32
10.44
12.85
17.47
20.09
22.37
19.6
18.04
17.67
16.59
16.79
- -
Book Value per Share
11.29
11.68
13.48
17.28
20.68
23.73
21.19
19.67
20.2
19.66
20.49
- -
Tangible Book Value per Share
22
39
45
45
45
45
45
45
45
45
45
- -
Basic Weighted Avg Shares
108
304
460
1,107
1,729
1,965
1,507
1,363
1,545
1,256
1,253
1,131
Sales/Revenue/Turnover
6.76
30.13
38.86
27.59
20.17
19.27
9.91
3.84
3.94
0.22
0.98
0.28
Operating Margin (%)
19
23
31
47
59
100
81
75
62
64
59
49
Depreciation Expense
7
117
170
229
271
286
118
37
25
2
19
8
Net Income, GAAP
- -
- -
17.79
24.33
23.52
22.93
25.18
44.27
63.8
85.61
25.24
48.24
Effective Tax Rate (%)
6.1
38.61
36.94
20.72
15.67
14.57
7.83
2.75
1.65
0.19
1.53
0.74
Profit Margin (%)
177
363
506
631
813
893
795
725
720
653
622
379
Working Capital
- -
- -
- -
- -
- -
97
84
125
93
89
95
78
LT Debt
250
453
609
823
976
1,112
991
922
942
916
948
926
Total Equity
- -
24.88
26.3
30.33
27.58
23.82
7.87
2.02
1.59
0.03
0.72
0.13
Return on Invested Capital (%)
- -
34.22
37.55
33.03
31.6
26.65
9.57
3.1
2.24
0.29
2.15
1.06
Return on Capital (%)
- -
35.86
34.64
33.51
31.89
29.78
12.44
4.41
3.15
0.3
2.54
1.11
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.47%
-1.27%
-2.3%
Free Cash Flow
-151.41%
-322.79%
-1,467.11%
Net Income, GAAP
51.33%
93.68%
-56.34%
Sales/Revenue/Turnover
21.37%
-4.98%
-9.76%
Total Cash Common Dividend
- -
200.91%
1,247.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,256
2024
- -
- -
- -
- -
1,253
2025
- -
- -
- -
- -
1,131

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.05
2024
- -
- -
- -
- -
0.42
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.46
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
- -
Similar Companies
TMC Life Sciences Berhad (0101.KL)
Azenta, Inc. (0HQ1.L)
MD Medical Group Investments Plc (MDMG.L)
Healwell AI Inc. (HWAIF)
LIMES Schlosskliniken AG (LIK.DE)
Universal Health Services, Inc. (UHID)
Business
Healthconn Corp. (6665.TWO) is a Taiwan-based provider of customized disease prevention, precision health management, and diagnostic services. Founded in 2009 and headquartered at 5/F, No. 54, Section 1, Zhongxiao East Road, Taipei, Taiwan, the company offers personal and corporate health management solutions; Smart Health 365 seamless year-round health services; health promotion programs encompassing nutrition, exercise, stress, and sleep management; telehealth services; cancer genetic testing; nutritional genomics and lifestyle optimization; food safety detection, oncogene detection, bacteriological examination, and molecular biology detection; precision diagnostic testing; diagnostic devices and smart testing solutions including blood collection tubes, needles, laboratory information systems, and automated lab integration; life science research support; and cold chain logistics with medical supply delivery. Healthconn operates primarily in Taiwan with subsidiaries in Hong Kong, Cayman Islands, Shenzhen, and Zhengzhou, targeting individual consumers, corporations, and healthcare providers through its HealthBee app and O2O platforms integrating genetic testing, precision instruments, and data management. In recent developments, the company presented an AI-based tuberculosis drug resistance prediction model with research partners at ESCMID Global 2025; secured the Taiwan agency rights for Tempus AI-driven cancer genetic testing in March 2025; partnered with Kemi in March 2024 to pursue smart medical opportunities; and through subsidiaries, expanded distribution with exclusive Taiwan rights for Techlab Diagnostic Products in 2021 and Ambry Genetics in 2020, alongside acquisitions such as 100% ownership of Kangyi Technology Co., Ltd. in 2017.